Insulin spending topped $22bn in 2022 and its costs have tripled in the last decade, with major producers following last year’s Inflation Reduction Act and setting a $35 cap on out-of-pocket expenditure. Despite big three firms dominating the market with cheaper versions of branded products, new alternatives are emerging, such as Civica Rx, a nonprofit planning $30 per-vial insulin by 2024, and the state-run CalRx scheme that’s focusing first on insulin.
Lazarus Hackers Exploiting IIS Servers to Deploy ASP-based Web Shells
The Lazarus group has launched sophisticated attacks on South Korean web servers, deploying ASP-based web shells as first-stage Command and Control (C2) servers. These attacks,
